Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin in metastatic melanoma
NCT00651157Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Dec 2011
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pelareorep in melanoma, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate and Toxicity Profile up to 5 years. Started Apr 2008; status: completed.
02
Drugs
pelareorep
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00651157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651157.